# Study to Determine D-amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After Single-dose Oral Administration

> **NCT02716987** · PHASE1 · COMPLETED · sponsor: **Neurocrine Biosciences** · enrollment: 20 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** TAK-831
- **DRUG:** [18F]PGM299

## Key facts

- **NCT ID:** NCT02716987
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-21
- **Primary completion:** 2016-08-30
- **Final completion:** 2016-08-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-06-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02716987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02716987, "Study to Determine D-amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After Single-dose Oral Administration". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02716987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*